Screening for XXXX : a pilot randomised controlled trial.

@entity43 @entity1 @entity5 @entity6887 @entity10224
BACKGROUND: The value of screening for @entity43 is uncertain. We did a pilot randomised trial to assess multimodal screening with sequential @entity10224 antigen and ultrasonography. METHODS: Postmenopausal @entity1 aged 45 years or older were randomised to a control group (n=10,977) or screened group (n=10,958). @entity1 randomised to screening were offered three annual screens that involved measurement of serum @entity10224 , pelvic ultrasonography if @entity10224 was 30 U/mL or more, and referral for gynaecological opinion if ovarian volume was 8.8 mL or more on ultrasonography. All @entity1 were followed up to see whether they developed @entity6887 (index @entity5 ). FINDINGS: Of 468 @entity1 in the screened group with a raised @entity10224 , 29 were referred for a gynaecological opinion; screening detected an index @entity5 in six and 23 had false-positive screening results. The positive predictive value was 20.7%. During 7-year follow-up, ten further @entity1 with index @entity5 were identified in the screened group and 20 in the control group. Median survival of @entity1 with index @entity5 in the screened group was 72.9 months and in the control group was 41.8 months (p=0.0112). The number of deaths from an index @entity5 did not differ significantly between the control and screened groups (18 of 10,977 vs nine of 10,958, relative risk 2.0 [95% CI 0.78-5.13]). INTERPRETATION: These results show that a multimodal approach to @entity43 screening in a randomised trial is feasible and justify a larger randomised trial to see whether screening affects mortality.
